Natalie Morrison

Journalist, illustrator, mug collector, all round geek. Writes on pharma and healthcare.

[Natalie Morrison @Morrison_Pharma]

@BBCScotlandNews Why isn’t the election map updating on your website?

[Natalie Morrison @Morrison_Pharma]

@kiss @kiss @Ticketmaster still has the gig as going ahead, even though it’s own website says all events are cancelled until 31st July. No word from @LiveNation either and it’s impossible or to get hold of anyone. Where do we go for help?

[Natalie Morrison @Morrison_Pharma]

A way to say thanks to our amazing @NHSuk workers - a scheme to buy them dinners so they don't have to fight for food in the supermarket and cook when they're exhausted. @MealsForTheNHS What a great initiative: https://t.co/kBCt1gsB9t #COVID19 #pandemic . #ThankYouNHS

[Natalie Morrison @Morrison_Pharma]

Some very handy graphs showing #COVID2019 infection and death rates in different countries

[Natalie Morrison @Morrison_Pharma]

Loss of smell could be a good indicator of a-symptomatic #COVID19 say ENT specialists: https://t.co/c9DP2colwm
#coronavirus

[Tom Meek @tmeek87]

#Pharma needs to do a better job communicating the value it adds to society through innovation, says @GSK CEO Emma Walmsley at #FTpharma conference

[Natalie Morrison @Morrison_Pharma]

@CatFeatherston @Expedeon1 @abcam Thanks Catherine! Hope you're well.

[Natalie Morrison @Morrison_Pharma]

@stamoran @Biopharma @apmhealtheurope Good point @stamoran. One idea raised here is that payers often won’t pay extra for a new product with improved mode of administration, for instance, if it’s more expensive than what is around and doesn’t offer efficacy benefits.

[Natalie Morrison @Morrison_Pharma]

How do we develop treatments for the disease symptoms which are most burdensome to patients? Pharma is not asking patients what they want from therapies. Experts discuss at #PPMAConf @BioPharma @apmhealtheurope

[Natalie Morrison @Morrison_Pharma]

‘Can cost-spreading for expensive new drug, cell and gene therapies really work considering more and more will be coming to market?’ payers at @PPMAConf ask. Read more @apmhealtheurope

[Natalie Morrison @Morrison_Pharma]

Experts discuss ways to include patients view across the drug development board, from discovery to HTA assessment and reimbursement at #PPMA2019

[Natalie Morrison @Morrison_Pharma]

Could conditional approval become the new norm for all medicines? Former CHMP chair Tomas Salmonson asks @TOPRANEWS audience #TOPRAsymposium @apmhealtheurope

[APM Health Europe @apmhealtheurope]

U.S. and French regulators among the leaders on microbiome therapeutics, says @MaaT_Pharma CEO Hervé Affagard. Read the full interview via @apmhealtheurope @Morrison_Pharma

[Natalie Morrison @Morrison_Pharma]

A similar approach to Google maps’ data sharing for traffic updates could be used for healthcare data, says Gary Leeming, Connected Health Cities #NICE_conf18 @apmhealtheurope

[Natalie Morrison @Morrison_Pharma]

Oral NSAIDs being prescribed without gastrointestinal protective medicines in UK shows gap in knowledge and implementation, say experts at NICE_conf18 @apmhealtheurope

[Natalie Morrison @Morrison_Pharma]

First time ‘yes’ in NICE technology appraisal is around 40% while 80% approved at FAD - experts discuss reasons @NICE_conf18 @apmhealtheurope

[Natalie Morrison @Morrison_Pharma]

Should NICE produce a guidance for implementation in the NHS? NICE’s Professor Gillian Leng asks NICE_conference audience in Manchester @apmhealtheurope

[Natalie Morrison @Morrison_Pharma]

NHS needs to focus on doing healthcare “with people and not to them” says Sir David Haslam, NICE_2018 @apmhealtheurope

[Natalie Morrison @Morrison_Pharma]

The newly knighted Sir David Haslam kicking off @NICE_2018 - looking forward to hearing he later on the NHS on it’s 70th birthday - via @apmhealtheurope

[Tom Meek @tmeek87]

U.S. needs prominent physician to stand up and support #biosimilar drugs to improve uptake, says Christine Simmon, @AccessibleMeds at #IGBAmedicinesforEU